Introductory paragraph
Identification of protective and/or pathogenic genetic modifiers provides important insight into the heterogeneity of disease presentations in individuals affected by neuromuscular disorders (NMDs), despite having well-defined pathogenic variants. Targeting modifier genes to improve disease phenotypes could be especially beneficial in cases where the causative genes are large, structurally complex and the mutations are heterogeneous.
Here, we report a mutation-independent strategy to upregulate expression of a compensatory disease-modifying gene in Congenital Muscular Dystrophy type 1A (MDC1A) using a CRISPR/dCas9-based transcriptional activation system. MDC1A is caused by nonfunctional Laminin α 2, which compromises muscle fibers stability and axon myelination in peripheral nerves 1 . Transgenic overexpression of Lama1, encoding a structurally similar protein Laminin α 1, ameliorates muscle wasting and paralysis in the MDC1A mouse models, demonstrating its role as a protective disease modifier 2 . Yet, upregulation of Lama1 as a postnatal gene therapy is hampered by its large size, which exceeds the current genome packaging capacity of clinically relevant delivery vehicles such as adeno-associated viral vectors (AAVs).
In this study, we sought to upregulate Lama1 using CRISPR/dCas9-based transcriptional activation system, comprised of catalytically inactive S. aureus Cas9 (dCas9) fused to VP64 transactivation domains and sgRNAs targeting the Lama1 promoter. We first demonstrated robust upregulation of Lama1 in myoblasts, and following AAV9-mediated intramuscular delivery, in skeletal muscles of dy 2j /dy 2j mouse model of MDC1A.
We therefore assessed whether systemic upregulation of Lama1 would yield therapeutic benefits in dy 2j /dy 2j mice. When the intervention was started early in pre-symptomatic dy 2j /dy 2j mice, Lama1 upregulation prevented muscle fibrosis and hindlimb paralysis. An important question for future therapeutic approaches for a variety of disorders concerns the therapeutic window and phenotypic reversibility. This is particularly true for muscular dystrophies as it has long been hypothesized that fibrotic changes in skeletal muscle represent an irreversible disease state that would impair any therapeutic intervention at advanced stages of the disease. Here, we demonstrate that dystrophic features and disease progression were significantly improved and partially reversed when the treatment was initiated in symptomatic 3-week old dy 2j /dy 2j mice with already-apparent hind limb paralysis and significant muscle fibrosis.
Collectively, our data demonstrate the feasibility and therapeutic benefit of CRISPR/dCas9-mediated modulation of a disease modifier gene, which opens up an entirely new and mutation-independent treatment approach for all MDC1A patients.
Moreover, this treatment strategy provides evidence that muscle fibrosis can be reversible, thus extending the therapeutic window for this disorder. Our data provide a proof-of-concept strategy that can be applied to a variety of disease modifier genes and a powerful therapeutic approach for various inherited and acquired diseases.
Congenital muscular dystrophy 1A (MDC1A) is an autosomal recessive neuromuscular disease associated with a high degree of morbidity and mortality in early childhood 1 One of the strongest reported disease modifiers for MDC1A is Laminin-α1 protein, which is structurally similar to Laminin-α2 (Fig. 1a) First, we mutagenized SaCas9 endonuclease catalytic residues (D10A, N580A) to create SadCas9 and then fused it to transcriptional activators VP64 (four copies of VP16) on both N-and C-termini (Fig. S1) . We tested the ability of the system, denoted as SadCas9-2xVP64, to upregulate the expression of minCMV-driven tdTomato gene in 293T cells 16 . In the absence of the SadCas9-2xVP64, the expression of tdTomato was undetectable due to the low baseline activity of minCMV promoter (Fig. S1a, b) . In the presence of SadCas9-2xVP64 in combination with an sgRNA targeting the minCMV locus, we observed high tdTomato fluorescence signal (Fig. S1c, d ), indicating the general applicability of this system to modulate expression of a gene of interest.
Subsequently, we tailored the system to upregulate Lama1 expression and designed five sgRNAs, denoted as g1 to g5, within the 500 nucleotides region immediately upstream of the Lama1 transcription start site (Figs. 1b, c) . When co-expressed with SadCas9-VP64 in C2C12 murine myoblasts, 3 out of 5 sgRNAs, namely g1, g2, and g5
consistently induced significant increase of Lama1 transcript expression (Figs. 1d, 
e).
Although all sgRNAs were designed to target a chromatin-accessible region derived from DNAse1 hypersensitivity-and assay for transposase-accessible chromatin (ATACSeq) sites (Fig. 1b) , g3 and g4 failed to increase expression of Lama1 above the basal level. This corroborates previously reported findings that chromatin accessibility is not a reliable predictor of successful gene activation 12, 17, 18 . Nonetheless, the sgRNA closest to the transcription start site, g1, and the combination of the three most optimum sgRNAs (g1, g2, g5) resulted in a robust increase in Lama1 protein expression in dy 2j /dy 2j -derived myoblasts (Figs. 1f, 1g ), warranting further investigation in vivo.
We then treated 3-week-old dy 2j /dy 2j mice with an AAV9 carrying FLAG-tagged SadCas9-2xVP64 in the absence of sgRNA (no guide) or with g1 (single guide) or a combination of g1, g2 and g5 (three guides) ( particles carrying either no guide or a combination of three guides were injected into the temporal vein of 2-day-old (P2) dy 2j /dy 2j mice (Fig. 3a) . Seven weeks post injection, the animals that received the three guides treatment showed an absence of classical hindlimb contracture, as opposed to the control group ( Fig. 3b; Supplementary videos 1 and 2). Western blot, immunofluorescence and H&E staining of TA and gastrocnemius muscles demonstrated robust expression of Lama1 on the sarcolemmal membrane ( Fig.   3c, 3d ), leading to ~50% reduction of fibrosis (Figs. 3e, 3f, S2 ).
We next examined the ability of Lama1 upregulation to reverse established muscular and peripheral nerve dysfunctions by initiating the treatment at 3-weeks of age, when paralysis was already apparent. We injected the dy 2j /dy 2j mice with increasing doses of AAV9 from 7.5x10 11 to 3x10 12 vector genomes via tail vein injection (Figs. S3, 4a) .
Expression of Lama1 was achieved in all doses tested (Fig. S3) , however, the highest dose of 3x10 12 vector genomes resulted in the most robust Lama1-positive muscle fibers (Fig. 4b, Fig. S3 ). Further analyses of the treated mice revealed strong Lama1 expression by Western blot (Fig. 4c) , significant improvement in muscle histopathology ( Fig. 4d) and approximately 50% reduction in the fibrotic area (Fig. 4e) compared to the no guide control group.
In addition to the skeletal muscle, Laminin α 2-deficiency also affects peripheral nervous system. Previous studies showed that the peripheral neuropathy phenotypes are alleviated exclusively in transgenic mice that overexpress Lama1 not only in the skeletal muscle, but also in the nerves 7 . We observed expression of Lama1 in the endoneurium of sciatic nerves in the treated mice (Fig. 4f) . Furthermore, specific tetanic force, which measures the aggregate torque produced by the dorsi flexor muscles, was also improved upon Lama1 upregulation (Fig. 4g) . In line with this finding, the degree of paralysis in the hind limbs and mobility of the treated mice were markedly improved ( One hurdle in developing a therapy for MDC1A is that the extent of heterogeneity of mutations often leads to variable disease severity and progression. Therefore, there is an urgent need to develop a universal, mutation-independent strategy that provides a treatment approach for all patients with MDC1A. Our study establishes a framework in which CRISPR/dCas9 transcriptional upregulation of a disease modifier gene, such as
Lama1, ameliorates disease symptoms in vivo and has the potential to be applied to all MDC1A patients, irrespective of their mutations.
Advances have been made towards elucidating MDC1A pathogenesis due to the availability of several mouse models with absent or reduced Lama2 expression. Yet, a crucial question facing therapeutic development and clinical trials in MDC1A is the reversibility of symptoms such as muscle fibrosis and significant paralysis. This issue, while critically important for therapeutic development, is difficult to address in patients 19 ,
but the ability to modify gene expression in postnatal animals allowed us to address this question and investigate the therapeutic window of intervention.
We have previously demonstrated that an early intervention using CRISPR/Cas9-mediated correction of a splicing defect resulted in robust Lama2 restoration and prevention of disease manifestation 4 . Here we showed that upregulation of Lama1, when initiated at pre-disease-onset, leads to similar prevention. Importantly, when the therapeutic intervention was initiated at older age, significant rescue of the phenotypes was attainable, indicating that post-symptomatic treatment provides a significant benefit in the dy 2j /dy 2j mouse model.
In addition to Lama1 upregulation described in this study, a number of disease modifying strategies are currently being explored in MDC1A animal models, such as treatment with miniaturized agrin [20] [21] [22] and laminin-α1 LN-domain nidogen-1 (αLNNd) [23] [24] [25] . dystrophin-deficient mouse models 27 . The most advanced approach is via delivery of Laminin-111 protein, although the efficacy remains low and the need to produce a large amount of bioactive protein is challenging 27 . In addition, the utilization of CRISPR/dCas9 system to upregulate Lama1 in mdx mice has been achieved locally via electroporation, which is not easily translatable into clinical settings 28 . Our strategy of employing AAVmediated S. aureus dCas9 to upregulate Lama1 in vivo may be tested further as a potential therapy in the context of Duchenne muscular dystrophy.
In addition to overcoming the cDNA size challenge for AAV9 packaging, our approach may also be superior in several cases where gene delivery does not lead to a complete rescue due to the use of mini promoters and/or minimal regulatory elements 29 . The CRISPR/dCas9-mediated transcriptional modulation acts directly on the endogenous locus, thereby maximizing the chance of successful upregulation and correct temporal and spatial expression patterns.
A very recent study by Liao et al described utilization of the CRISPR/Cas9 system to recruit MCP:P65:HSF1 transcriptional activation complex to induce expression of target genes in skeletal muscle, kidney and liver tissues 18 . This resulted in phenotypic augmentation such as enhanced muscle mass and substantial improvement in disease pathophysiology, thereby highlighting the feasibility of using CRISPR/dCas9-mediated transcriptional activation as a possible therapeutic modality. However, their study relied almost exclusively on a Cas9-expressing transgenic mouse model or local intramuscular treatments, and therefore it is difficult to extrapolate the efficacy of this strategy to disease-relevant models. In contrast, we successfully demonstrated robust upregulation of Lama1 after systemic delivery of therapeutic components in a relevant mouse model of disease that does not constitutively express Cas9.
Finally, the modular nature of the CRISPR/dCas9 system can be utilized to not only to upregulate, but also to downregulate target gene expression. The latter can be achieved by coupling dCas9 with transcriptional repressor such as Kruppel-associated box (KRAB) 17, 30 . A very recent study described that following sarcolemmal injury, the muscle membrane resealing process is greatly improved upon the deletion of Osteopontin, which acts in a concerted fashion with protective modifiers such as Latent TGF-β binding protein (LTBP4) and Annexins 1 and 6 31, 32 . The combinatorial effects of such modifiers, whether they are additive, synergistic or even opposing in action, represent a new paradigm for lessening disease phenotypes. A foreseeable application of CRISPR/dCas9-mediated modulation in the future is in the upregulation of protective disease modifier genes, such as Lama1 or LTBP4, with concurrent downregulation of detrimental genes, such as Osteopontin, providing a combinatorial therapeutic approach.
In summary, our study establishes a framework to utilize CRISPR/dCas9 to modulate gene expression of disease modifiers that should be considered as a mutationindependent therapeutic strategy not only to MDC1A, but also to various other inherited and acquired diseases.
Methods

Engineering of Activation S. aureus dCas9, Cloning and Virus Production
A fragment containing a catalytically inactive SaCas9 coupled to two flanking VP64 transactivator domains was synthesized by BioBasic Canada and cloned into pX601 (Addgene 61591) using AgeI and EcoRI directional cloning to generate 3XFLAG-VP64-SadCas9 (D10A/N580A)-NLS-VP64 plasmid (Fig. S4) . Each sgRNA (Supplementary and brought up to 50uL with 1xPBS (Gibco).
Cell Culture
Primary myoblasts were isolated from the Extensor Digitorum Longus (EDL) Muscle of dy 2J /dy 2J mice, as previously described 33 and maintained in DMEM supplemented with 1% chicken embryo extract (GeminiBioscience), 10% horse serum, 1%
penicillin/streptomycin and 1% L-glutamine (all from Gibco, unless indicated otherwise).
HEK293 and C2C12 cells where maintained in DMEM supplemented with 10% FBS, 1%
penicillin/streptomycin and 1% L-glutamine (all from Gibco). All cells were maintained at 37 o C with 5% CO 2 .
Transfection of HEK293T cells was performed as previously described 2 . C2C12 and dy 2J /dy 2J cells were transfected in 12-well plates using the Neon Transfection System (Invitrogen). 400,000 cells were electroporated with 1.5ug of DNA utilizing optimization program 16 (pulse voltage: 1400V, pulse width: 20ms, pulse number: 2). Cells were grown for 72 hours, after which RNA or protein was subsequently collected for protein analysis and guide screening.
RNA isolation, guide screening and RT-PCR
RNA was isolated from cultured cells and mouse tissue sections, and cDNA synthesis was performed as previously described 3 . PCR amplification was utilized to assess the efficiency of each guide in upregulating Lama1 expression using a primer in Lama1 exon 55 (RDC 1919) and a second primer spanning the junction of exons 55 and 56 (RDC 1920 
Δ Δ
Ct was analyzed to assess fold changes between treated and untreated samples.
Protein Isolation and western blot
Protein was isolated from dy 2J /dy 2J , and C2C12 cells by adding 150uL of a 1:1 part solution of RIPA homogenizing buffer (50-mM Tris HCl pH 7.4, 150-nM NaCl, 1-mM EDTA) and RIPA double-detergent buffer (2% deoxycholate, 2% NP40, 2% Triton X-100
in RIPA homogenizing buffer) supplemented with protease-inhibitor cocktail (Roche).
Cells were subsequently scraped from the bottom of each well, collected and incubated on ice for 30 min. Cells then centrifuged at 12000xg for 15 min at 4 o C and the supernatant was collected and stored at -80 o C. Protein from mouse tissue sections was collected as previously described 3 . Whole protein concentration was measured using
Pierce BCA protein assay kit according to the manufacturer's protocol (Thermo Fisher Scientific). Western blot was performed as previously described 3 . Primary antibodies used were rabbit Anti-LNα1 E3 (a gift from Dr. Peter Yurchenco, 0.6 μ g/ml), mouse monoclonal M2 anti-Flag (Sigma Aldrich F1804, 1:1000) and rabbit polyclonal anti-GAPDH (Santa Cruz sc-25778, 1:5000).
Immunofluorescence and H&E staining
Antibodies used for immunofluorescence staining were rat anti-200 LNα1 (Durbeej Laboratory, 1:20), mouse anti-NF-H (Biolegend SMI 31, 1:1000), goat polyclonal anti-rat Alexa Fluor 555 (Thermo Fisher Scientific, 1:250) and goat polyclonal anti-mouse Alexa
Fluor 488 (Thermo fisher Scientific, 1:250). H&E staining was performed as previously described 4 . Both immunofluorescence and H&E slides were scanned with the 3Dhistech
Pannoramic 250 Flash II digital scanner and analyzed with CaseViewer software.
Morphometric analysis was performed as previously described 4 .
Animal Studies and Functional tests
dy 2j /dy 2j mice were purchased from the Jackson Laboratory and maintained in the Toronto Center for Phenogenomics. All animal experiments were performed according to Animal Use Protocol number 16-0234H. Intramuscular and temporal vein injections were preformed as previously described 4 . Systemic administration experiments were performed on 3-week-old dy 2j /dy 2j mice through tail vein injection. All functional tests were performed as previously described 4 .
Statistical Analysis
GraphPad Prism (GraphPad software) was utilized to preform all statistical analyses.
Two-tailed Student' t-tests to evaluate statistical significance between two groups was preformed. Significance was considered to be P < 0.05.
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